Pay in 4 interest-free payments of $5.96 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
doi: 10.1136/heartjnl-2018-314086 116 LuHDaughertyA
Because obesity is recognized as a chronic disease by major medical associations, treatments for itincluding GLP-1 medications are typically considered qualified expenses
However, employers on a self-funded plan often have more control over their pharmacy benefits and can dictate which coverage tier they want to impose as well as whether they want the drug to be limited only to diabetic treatment or allow for expanded usage under weight loss treatments
Not only did I reach my goal weight in under a year, I found the health practictioners to be responsive and helpful
In February, researchers from the University of Leicester and the Leicester Diabetes Centre published a review article on obesity in the "International Journal of Obesity," introducing the current and future drug development pipeline for the treatment of obesity, with special attention given to novel therapies based on the mechanisms of gut incretin hormones
US$ 27.20
US$ 23.10
US$ 27.39
